奈韦拉平和依非韦伦治疗HIV感染的长期效果和安全性比较

Comparison of long-term efficacy and safety of nevirapine and efavirin in the treatment of HIV infection

目的:探讨奈韦拉平和依非韦伦治疗人类免疫缺陷病毒(HIV)感染的长期效果和安全性。方法:2014年9月-2016年9月收治艾滋病HIV感染患者88例,随机分为两组,各44例。A组采用奈韦拉平治疗,B组采用依非韦伦治疗,比较两组患者病毒学疗效和CD4+T淋巴细胞计数。结果:两组治疗12个月、24个月、36个月和48个月的病毒抑制效果比较,差异无统计学意义(P>0.05);两组治疗12个月、24个月、36个月和48个月的CD4^(+)T淋巴细胞增殖比较,差异无统计学意义(P>0.05);A组消化道症状、皮疹发生率高于B组,A组中枢神经症状发生率低于B组,差异均有统计学意义(P<0.05)。结论:奈韦拉平和依非韦伦治疗HIV感染的长期效果大体类似,但不良反应的类型有所不同,临床上可根据不同人群的特点,谨慎选择。

Objective:To explore the long-term efficacy and safety of nevirapine and efavirin in the treatment of HIV infection.Methods:From September 2014 to September 2016,88 cases of AIDS HIV infection were selected.They were randomly divided into two groups with 44 cases in each group.Group A was treated with nevirapine.Group B was treated with efavirin.We compared the virological efficacy and CD4+T lymphocyte count between the two groups.Results:There was no significant difference in virus inhibition effect between the two groups at 12 months,24 months,36 months and 48 months after treatment(P>0.05).There was no significant difference in CD4+T lymphocyte proliferation between the two groups at 12 months,24 months,36 months and 48 months after treatment(P>0.05).In group A,the incidence of gastrointestinal symptoms and rash was higher than that in group B,and the incidence of central nervous system symptoms was lower than that in group B,the difference was statistically significant(P<0.05).Conclusion:The long-term effects of nevirapine and efavirin in the treatment of HIV infection are generally similar,however,the types of adverse reactions are different.Clinically,they can be selected carefully according to the characteristics of different populations.